We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Targeting the Engine Room of the Cancer Cell

News   Jun 19, 2018 | Original story from Columbia University Irving Medical Center (CUIMC)

 
Targeting the Engine Room of the Cancer Cell

The pipeline consists of a series of pre-computed (*) components, including a reference set of more than 13,000 tumor expression profiles representing 35 different tumor types, a collection of 28 tissue context-specific interactomes and a database of context-specific mechanism of action (MoA) for >400 FDA-approved drugs and investigational compounds in oncology. The transcriptome of the perturbed cell lines is profiled at low cost by PLATE-Seq. The process begins with the expression profile of a single patient sample, which is compared against the tumor databank to generate a tumor gene expression signature. This signature is interpreted by VIPER using a context-matched interactome to identify the set of most dysregulated proteins, which constitute the regulators of the tumor cell state -- tumor checkpoint. These proteins are then aligned against the drugs' and compounds' MoA database, to prioritize compounds able to invert the activity pattern of the tumor checkpoint. Credit: CUIMC/Califano Lab

 
 
 

RELATED ARTICLES

Toxin in Bacteria Hijacks and Modifies Human Proteins

News

A team of scientists discovered that the toxin SidJ in Legionella bacteria enforces a unique modification on human proteins and helps legionella grow inside human cells.

READ MORE

Algorithms Could Make Breast Cancer Diagnosis Easier

News

Breast ultrasound elastography is an emerging imaging technique that provides information about a potential breast lesion by evaluating its stiffness in a non-invasive way. At the crux of this procedure, however, is a complex computational problem that can be time-consuming and cumbersome to solve. Can algorithms help?

READ MORE

Targeting Enzyme “Bottleneck” Reveals Novel Anticancer Drug Strategy

News

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists have now identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE